Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Status:
Completed
Trial end date:
2019-06-01
Target enrollment:
Participant gender:
Summary
Limited stage Hodgkin lymphoma is a highly curable disease, but standard treatment with ABVD
chemotherapy and radiation can lead to late risks of secondary cancers, lung injury, heart
injury, and others. This trial eliminates radiation therapy and reduces intensity of
chemotherapy by incorporating the highly active FDA-approved targeted therapy brentuximab
vedotin, an antibody-drug conjugate specifically against the lymphoma cells, combined with
the standard chemotherapy drugs Adriamycin and Dacarbazine (AD).